Veeva Systems (NYSE:VEEV) Releases FY 2026 Earnings Guidance

Veeva Systems (NYSE:VEEV) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 7.930-7.93 for the period, compared to the consensus earnings per share estimate of 6.890. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion. Veeva Systems also updated its Q4 2026 guidance to 1.920-1.920 EPS.

Veeva Systems Price Performance

Veeva Systems stock traded down $1.99 during mid-day trading on Thursday, reaching $271.01. 1,753,450 shares of the company traded hands, compared to its average volume of 1,290,035. Veeva Systems has a 52-week low of $201.54 and a 52-week high of $310.50. The firm has a market capitalization of $44.42 billion, a price-to-earnings ratio of 55.65, a P/E/G ratio of 2.22 and a beta of 0.98. The firm’s 50 day moving average price is $288.57 and its 200 day moving average price is $278.53.

Veeva Systems (NYSE:VEEV) last posted its earnings results on Thursday, November 20th. The technology company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The firm had revenue of $811.24 million during the quarter, compared to analysts’ expectations of $792.37 million. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS. Q4 2026 guidance at 1.920-1.920 EPS. On average, sell-side analysts anticipate that Veeva Systems will post 4.35 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VEEV. Truist Financial upped their target price on Veeva Systems from $268.00 to $275.00 and gave the stock a “hold” rating in a report on Thursday, August 28th. Morgan Stanley lifted their price target on Veeva Systems from $210.00 to $222.00 and gave the company an “underweight” rating in a research report on Thursday, August 28th. Canaccord Genuity Group increased their price objective on Veeva Systems from $270.00 to $300.00 and gave the stock a “hold” rating in a report on Thursday, August 28th. Wall Street Zen cut shares of Veeva Systems from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $355.00 price target on shares of Veeva Systems in a research note on Friday, October 17th. Seventeen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Veeva Systems presently has an average rating of “Moderate Buy” and a consensus price target of $307.28.

Insider Activity

In other news, SVP Jonathan Faddis sold 14,595 shares of Veeva Systems stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $300.00, for a total value of $4,378,500.00. Following the completion of the transaction, the senior vice president owned 8,588 shares of the company’s stock, valued at $2,576,400. The trade was a 62.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the sale, the insider directly owned 25,325 shares in the company, valued at $7,765,151.50. This trade represents a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 24,665 shares of company stock worth $7,438,000 over the last three months. 10.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Veeva Systems

A number of hedge funds have recently added to or reduced their stakes in VEEV. Williams Jones Wealth Management LLC. boosted its stake in Veeva Systems by 0.4% during the 3rd quarter. Williams Jones Wealth Management LLC. now owns 9,419 shares of the technology company’s stock valued at $2,806,000 after purchasing an additional 40 shares during the last quarter. Rafferty Asset Management LLC raised its stake in shares of Veeva Systems by 0.7% in the second quarter. Rafferty Asset Management LLC now owns 6,881 shares of the technology company’s stock worth $1,982,000 after purchasing an additional 51 shares during the last quarter. Brown Brothers Harriman & Co. lifted its holdings in shares of Veeva Systems by 8.1% during the third quarter. Brown Brothers Harriman & Co. now owns 719 shares of the technology company’s stock valued at $214,000 after purchasing an additional 54 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of Veeva Systems by 56.7% during the second quarter. Rakuten Securities Inc. now owns 163 shares of the technology company’s stock valued at $47,000 after purchasing an additional 59 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of Veeva Systems by 4.9% during the third quarter. Parallel Advisors LLC now owns 1,297 shares of the technology company’s stock valued at $387,000 after buying an additional 61 shares during the last quarter. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.